You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
We first fit a random-effects model using the binomial likelihood with logit link. We use vague priors for heterogeneity and relative effects.
79
+
We first fit a random-effects model using the binomial likelihood with logit link. We use weakly informative priors for heterogeneity and relative effects.
We find the following estimate for tau, the between-study standard deviation: `r round(tau_consistency, 3)`. The DIC for this model is `r round(dic_consistency$dic, 1)`.
106
-
107
96
To complement the relative treatment effects, we summarize the probability that each treatment ranks among the best options in reducing COPD exacerbations.
108
97
Cumulative rank probabilities provide a visual summary of the likelihood that a given treatment occupies each possible rank position, with higher curves indicating a higher probability of superior performance.
109
98
@fig-rankprobs displays these probabilities for all treatments included in the network meta-analysis, using placebo as the reference.
To complement the ranking results, we next assess the overall model fit and between‐study heterogeneity. Specifically, we extract the Deviance Information Criterion (DIC) and the estimated between‐study standard deviation ($\tau$) from the consistency model, which will later be compared with those from the UME model.
We find the following estimate for $\tau$, the between-study standard deviation: `r round(tau_consistency, 3)`. The DIC for this model is `r round(dic_consistency$dic, 1)`.
123
129
124
130
## Assessing Inconsistency
125
131
To assess local inconsistency, we apply the node-splitting approach to each comparison with both direct and indirect evidence.
@@ -136,7 +142,14 @@ nma_inconsistency <- nma(
136
142
prior_het = half_normal(scale = 2.5),
137
143
refresh = 0
138
144
)
145
+
```
139
146
147
+
We can again assess the overall model fit and between‐study heterogeneity, and compare it to the resuls from the consistency model:
We estimated the between-study heterogeneity parameter, $\tau$, to be `r round(tau_inconsistency, 3)`. For the same model, the Deviance Information Criterion (DIC) was `r round(dic_inconsistency$dic, 1)`, providing an overall measure of model fit that balances goodness-of-fit and model complexity.
170
+
```{r}
171
+
#| echo: false
172
+
#| message: false
173
+
#| warning: false
174
+
kable(model_comparison)
175
+
```
151
176
152
177
To further explore model fit and potential inconsistency, we compared the residual deviance contributions from the consistency and UME models. Each point in the plot below represents the contribution of a study–treatment arm to the overall residual deviance. Points lying below the diagonal indicate observations that are better explained under the UME (inconsistent) model, suggesting potential sources of inconsistency.
153
178
@@ -187,7 +212,8 @@ Finally, we can identify data points with substantial differences in residual de
187
212
#| warning: false
188
213
189
214
resdev_joined %>%
190
-
filter(abs(resdev_cons - resdev_ume) > 1)
215
+
filter(abs(resdev_cons - resdev_ume) > 1) %>%
216
+
as.data.frame()
191
217
```
192
218
193
219
The results indicate that most studies fit both models similarly, with only the van Noord (2005) study -- specifically the Tiotropium and Formoterol arms -- showing improved fit under the UME model. This pattern points to possible local inconsistency associated with that study.
0 commit comments